CMS backs off Part D revision

Share this article:

The proposal to reduce the number of drugs Medicare Part D has to cover among certain classes is dead. CMS Administrator Marilyn Tavenner sent a note to Rep. Henry Waxman (D-CA) Monday saying that her agency would no longer pursue the change based on stakeholder feedback, or, as Politico described it, “withering criticism from the industry, patient advocacy groups and lawmakers.”

Waxman is the ranking member of the House Energy and Commerce Committee.

CMS issued the proposal in January. The aim was to limit the options in three drug classes, for cost control reasons, but the financial argument was as much an industry irritant as it was a political one.

Modern Healthcare described Monday's move as “political cover ahead of the mid-term elections,” and noted that the overall draft, which included this Medicare Part D drug proposal was “universally panned.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.